NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 348 filers reported holding NEKTAR THERAPEUTICS in Q4 2018. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2019 | $38,554,000 | -7.4% | 1,083,598 | -12.5% | 3.03% | -8.1% |
Q1 2019 | $41,613,000 | +11.6% | 1,238,489 | +9.2% | 3.29% | +6.0% |
Q4 2018 | $37,288,000 | -46.1% | 1,134,414 | 0.0% | 3.11% | -22.3% |
Q3 2018 | $69,154,000 | +24.8% | 1,134,414 | 0.0% | 4.00% | +33.3% |
Q2 2018 | $55,393,000 | -22.0% | 1,134,414 | +69.7% | 3.00% | -30.3% |
Q1 2018 | $71,034,000 | -13.0% | 668,492 | -51.1% | 4.31% | -20.1% |
Q4 2017 | $81,647,000 | +49.6% | 1,367,171 | -39.9% | 5.39% | +64.9% |
Q3 2017 | $54,592,000 | -0.7% | 2,274,661 | -19.1% | 3.27% | +4.2% |
Q2 2017 | $54,957,000 | -20.3% | 2,811,092 | -4.3% | 3.14% | -20.3% |
Q1 2017 | $68,937,000 | +42.4% | 2,937,255 | -25.5% | 3.93% | +16.9% |
Q4 2016 | $48,401,000 | -0.5% | 3,944,692 | +39.3% | 3.36% | +2.6% |
Q3 2016 | $48,665,000 | -5.0% | 2,832,636 | -21.3% | 3.28% | -0.8% |
Q2 2016 | $51,207,000 | +5.9% | 3,598,554 | +2.3% | 3.31% | -1.0% |
Q1 2016 | $48,359,000 | +83.5% | 3,517,011 | +124.9% | 3.34% | +283.7% |
Q4 2015 | $26,351,000 | – | 1,563,862 | – | 0.87% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
TOBAM | 640,547 | $21,522,000 | 1.09% |
Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |